653 related articles for article (PubMed ID: 30429124)
1. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
[TBL] [Abstract][Full Text] [Related]
2. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Pasternak B; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Ueda P
BMJ; 2020 Apr; 369():m1186. PubMed ID: 32349963
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation.
Kmietowicz Z
BMJ; 2018 Nov; 363():k4828. PubMed ID: 30429136
[No Abstract] [Full Text] [Related]
4. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378
[TBL] [Abstract][Full Text] [Related]
5. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
Diabetes Obes Metab; 2018 Dec; 20(12):2792-2799. PubMed ID: 29971914
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM
Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419
[TBL] [Abstract][Full Text] [Related]
7. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
[TBL] [Abstract][Full Text] [Related]
8. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Donnan JR; Grandy CA; Chibrikov E; Marra CA; Aubrey-Bassler K; Johnston K; Swab M; Hache J; Curnew D; Nguyen H; Gamble JM
BMJ Open; 2019 Feb; 9(1):e022577. PubMed ID: 30813108
[TBL] [Abstract][Full Text] [Related]
10. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.
Patil T; Cook M; Hobson J; Kaur A; Lee A
Am J Cardiol; 2023 Aug; 201():281-293. PubMed ID: 37393731
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
[TBL] [Abstract][Full Text] [Related]
13. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
14. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
15. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
16. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
Fralick M; Kim SC; Schneeweiss S; Kim D; Redelmeier DA; Patorno E
Ann Intern Med; 2019 Feb; 170(3):155-163. PubMed ID: 30597484
[TBL] [Abstract][Full Text] [Related]
17. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
18. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Nadkarni GN; Ferrandino R; Chang A; Surapaneni A; Chauhan K; Poojary P; Saha A; Ferket B; Grams ME; Coca SG
Diabetes Care; 2017 Nov; 40(11):1479-1485. PubMed ID: 28827404
[TBL] [Abstract][Full Text] [Related]
19. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.
Engström A; Wintzell V; Melbye M; Hviid A; Eliasson B; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B; Ueda P
Diabetes Care; 2023 Feb; 46(2):351-360. PubMed ID: 36508322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]